Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 4/20 | 0.65 |
| ▸ | GSK3B | P49841 | 3/20 | 0.65 |
| ▸ | KIT | P10721 | 2/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | JAK3 | P52333 | 8/20 | 0.55 |
| ▸ | JAK2 | O60674 | 3/20 | 0.55 |
| ▸ | JAK1 | P23458 | 2/20 | 0.55 |
| ▸ | TYK2 | P29597 | 2/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.53 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7853366 | 0.95 | AKT2 (0.58) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL2048915 | 0.86 | AKT2 (0.70) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL7852543 | 0.81 | AKT2 (0.63) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL3955148 | 0.81 | AKT2 (0.74) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL4125661 | 0.79 | AKT2 (1.00) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL2022114 | 0.78 | AKT2 (0.69) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL9938728 | 0.77 | KIT (0.62) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL1003408 | 0.76 | AKT2 (1.00) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL30673936 | 0.76 | AKT2 (1.00) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL2022699 | 0.76 | AKT2 (0.78) | AKT2GSK3BKITLCKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569569-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2009-08-04 | — | — | US | disclosed |
| EP-1087971-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040058922-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2004-03-25 | — | — | US | disclosed |
| US-6635762-B1 | Protein tyrosine kinase or Janus Kinase 3 inhibitors; immunosuppressants | PFIZER INC. | 2003-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058922-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | AKT2 731/4885GSK3B 666/4885KIT 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.